Coronary artery disease remains the leading cause of morbidity and mortality in the Western society and is expected to be the leading cause of morbidity and mortality worldwide. It becomes apparent that in order to attenuate the disease process, clinical investigation into the mechanism, diagnosis and treatment of early coronary atherosclerosis is crucial. Early coronary atherosclerosis is associated with altered coronary endothelial function prior to the development of significant atherosclerotic disease. This disease stage is characterized by coronary vasoconstriction and reduction or attenuated coronary vasorelaxant response to the endothelial-dependent vasodilators such as acetylcholine and is associated with myocardial perfusion defects consistent with myocardial ischemia and an increase in cardiac events. Thus, the current K-24 application seeks to support the principal investigator to devote time to patient-oriented research and to act as a mentor for beginning clinical investigators in the area of early coronary atherosclerosis and endothelial function in humans. The exceptional patient-oriented research environment at the Mayo Clinic further optimized by the auspices of the Mayo Clinic Cardiac Catheterization Laboratory constitutes a unique resource to address these questions thereby providing a rich experience in patient oriented research to junior investigators. Thus, building on methods implemented during the P.I.?s R01 grant, in conjunction with novel and prospective approaches, the objective of this K24 application is to develop a program to mentor future investigators in patient-oriented research. The broad scientific aims of this application are: 1) to determine the role of endothelial humoral regulation of the coronary circulation with a specific focus upon endothelin and oxidative stress in early coronary atherosclerosis and endothelial dysfunction in humans; 2) to examine the associations between conventional and non-conventional risk factors as well as genetic predisposition and coronary endothelial function; 3) to develop novel non-invasive tests as well as peripheral markers for early diagnosis of coronary endothelial dysfunction; 4) to assess the relationship between coronary endothelial function and structure in humans with early coronary atherosclerosis; and 5) to address prospectively the prognosis of coronary endothelial function in humans. The success of this program has the potential to further both the research and mentoring endeavors of patient-oriented investigation and mentoring the next generation of patient-oriented researchers.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24HL069840-04
Application #
6938550
Study Section
Special Emphasis Panel (ZHL1-CSR-F (F1))
Program Officer
Scott, Jane
Project Start
2002-09-30
Project End
2007-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
4
Fiscal Year
2005
Total Cost
$98,709
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Reriani, Martin; Sara, Jaskanwal D; Flammer, Andreas J et al. (2016) Coronary endothelial function testing provides superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events. Coron Artery Dis 27:213-20
Reriani, Martin; Flammer, Andreas J; Li, Jing et al. (2014) Microvascular endothelial dysfunction predicts the development of erectile dysfunction in men with coronary atherosclerosis without critical stenoses. Coron Artery Dis 25:552-7
Topilsky, Yan; Raichlin, Eugenia; Hasin, Tal et al. (2013) Combined heart and liver transplant attenuates cardiac allograft vasculopathy compared with isolated heart transplantation. Transplantation 95:859-65
Yoon, Myeong Ho; Reriani, Martin; Mario, Gossl et al. (2013) Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol 168:1316-21
Herrmann, Joerg; Wohlert, Christine; Saguner, Ardan M et al. (2013) Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 15:614-23
Mannheim, Dallit; Herrmann, Joerg; Bonetti, Piero O et al. (2011) Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis 216:283-91
Rubinshtein, Ronen; Yang, Eric H; Rihal, Charanjit S et al. (2010) Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J 31:936-42
Reriani, Martin; Raichlin, Eugenia; Prasad, Abhiram et al. (2010) Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 122:958-66
Herrmann, Joerg; Lerman, Lilach O; Lerman, Amir (2010) On to the road to degradation: atherosclerosis and the proteasome. Cardiovasc Res 85:291-302
Gössl, Mario; Versari, Daniele; Hildebrandt, Heike A et al. (2010) Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis. JACC Cardiovasc Imaging 3:32-40

Showing the most recent 10 out of 55 publications